Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Shares Outstanding (Weighted Average)
Others
Ratios

RAPT Therapeutics (RAPT) Income from Continuing Operations: 2020-2023

Historic Income from Continuing Operations for Therapeutics (RAPT) over the last 4 years, with Dec 2023 value amounting to -$33.2 million.

  • Therapeutics' Income from Continuing Operations fell 35.96% to -$33.2 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$127.1 million, marking a year-over-year decrease of 48.10%. This contributed to the annual value of -$127.1 million for FY2023, which is 48.10% down from last year.
  • As of Q4 2023, Therapeutics' Income from Continuing Operations stood at -$33.2 million, which was up 2.07% from -$33.9 million recorded in Q3 2023.
  • Therapeutics' 5-year Income from Continuing Operations high stood at -$12.4 million for Q2 2020, and its period low was -$33.9 million during Q3 2023.
  • In the last 3 years, Therapeutics' Income from Continuing Operations had a median value of -$21.2 million in 2022 and averaged -$23.5 million.
  • Data for Therapeutics' Income from Continuing Operations shows a maximum YoY slumped of 56.47% (in 2023) over the last 5 years.
  • Over the past 4 years, Therapeutics' Income from Continuing Operations (Quarterly) stood at -$12.7 million in 2020, then slumped by 40.79% to -$17.9 million in 2021, then slumped by 36.27% to -$24.4 million in 2022, then plummeted by 35.96% to -$33.2 million in 2023.
  • Its Income from Continuing Operations stands at -$33.2 million for Q4 2023, versus -$33.9 million for Q3 2023 and -$28.4 million for Q2 2023.